Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...

The liver is one of the body’s most vital organs, working tirelessly behind the scenes to detoxify, regulate metabolism, ...

The Post caught up with several stars and crew members of “The Handmaid’s Tale” at the show’s sixth and final season premiere ...

In the latest market close, Gilead Sciences (GILD) reached $112.39, with a +0.45% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of 4.84%. On ...

PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...

"We tried not to make the same show — it's got younger voices, it's got a completely different feel and a completely ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...

Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...

As the sixth and final season lands on Hulu, THR’s chief TV critic reflects on how the dystopian series was shaped by the ...

Hulu announced that it is developing a series based on Margaret Atwood's 2019 novel "The Testaments," which is a follow-up to ...

The final season of "The Handmaid's Tale," premiering April 8 on Hulu, expands the themes and story of Margaret Atwood's ...